186 related articles for article (PubMed ID: 32886076)
1. [Literature review in the diagnosis and treatment of malignant pheochromocytomas and paragangliomas.].
Militello C; Jorge C; Pisani J; Cenice F; Chagra C
Arch Esp Urol; 2020 Sep; 73(7):611-623. PubMed ID: 32886076
[TBL] [Abstract][Full Text] [Related]
2. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW
Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056
[TBL] [Abstract][Full Text] [Related]
3. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
[TBL] [Abstract][Full Text] [Related]
6. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
9. Paragangliomas and Pheochromocytomas: Positron Emission Tomography/Computed Tomography Diagnosis and Therapy.
Marcus C; Subramaniam RM
PET Clin; 2023 Apr; 18(2):233-242. PubMed ID: 36585340
[TBL] [Abstract][Full Text] [Related]
10. Use of 131I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma.
Swensen SJ; Brown ML; Sheps SG; Sizemore GW; Gharib H; Grant CS; van Heerden JA
Mayo Clin Proc; 1985 May; 60(5):299-304. PubMed ID: 3990377
[TBL] [Abstract][Full Text] [Related]
11. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy.
Quint LE; Glazer GM; Francis IR; Shapiro B; Chenevert TL
Radiology; 1987 Oct; 165(1):89-93. PubMed ID: 3628794
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytomas and Hypertension.
Pappachan JM; Tun NN; Arunagirinathan G; Sodi R; Hanna FWF
Curr Hypertens Rep; 2018 Jan; 20(1):3. PubMed ID: 29356966
[TBL] [Abstract][Full Text] [Related]
13. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
14. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.
Fishbein L
Hematol Oncol Clin North Am; 2016 Feb; 30(1):135-50. PubMed ID: 26614373
[TBL] [Abstract][Full Text] [Related]
17. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
18. Pheochromocytomas and Paragangliomas.
Tevosian SG; Ghayee HK
Endocrinol Metab Clin North Am; 2019 Dec; 48(4):727-750. PubMed ID: 31655773
[TBL] [Abstract][Full Text] [Related]
19. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic approach of pheochromocytomas and paragangliomas].
Gómez RM; Hernaiz M; de Miguel V; Aparicio LS; Marín MJ; Lupi S; Barontini M;
Hipertens Riesgo Vasc; 2019; 36(1):34-43. PubMed ID: 30078655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
